Bailard, Inc. Caribou Biosciences, Inc. Transaction History

Bailard, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 02, 2023	SELL	$5.57 - $11.01 $30,545 - $60,378	-5,484 Reduced 27.84%	14,216 $89,000
Q3 2022 Oct 18, 2022	SELL	$5.34 - $12.79 $20,292 - $48,602	-3,800 Reduced 16.17%	19,700 $208,000
Q2 2022 Jul 27, 2022	BUY	$5.1 - $9.74 $119,849 - $228,890	23,500 New	23,500 $128,000
Q4 2021 Feb 10, 2022	SELL	$14.59 - $23.26 $128,392 - $204,688	-8,800 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$15.75 - $30.29 $138,600 - $266,552	8,800 New	8,800 $210,000

135

52.6M

148K

70.7K

Ticker CRBU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,840,800
Market Cap $98M
Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

Stay updated on Bailard, Inc. with notifications on news.